Advertisement

Organisation › Details
Byondis (Group)
Driven to improve patients’ lives, Byondis is an independent biopharmaceutical research and development company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other biopharmaceutical companies by its proprietary molecular concepts, such as its linker-drug (LD) and site-specific conjugation technologies to generate antibody-drug conjugates (ADCs). Byondis’ broad development portfolio comprises preclinical and early- and late-stage clinical programs, including the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985, Phase III). The company has a dedicated team of more than 350 staff including highly educated scientists and skilled technicians working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. Byondis collaborates with global biotechnology and pharmaceutical companies and national and international academic research institutions. *
![]() |
Start | 2020-04-16 renamed |
Today | Byondis B.V. | |
Predecessor | Synthon Biopharmaceuticals B.V. | |
![]() |
Industry | drug development |
Industry 2 | antibody-drug conjugate (ADC) | |
![]() |
Person | Timmers, Marco (Byondis 202008 CEO) |
Person 2 | Van Heekeren, Robbert (Byondis 202009– CFO before Odyssee Mobile + Kiadis Pharma + Proxy Laboratories + Organon) | |
![]() |
Region | Nijmegen |
Country | Netherlands | |
Street | 22 Microweg P.O. Box 6570 | |
City | 6503 GB Nijmegen | |
Tel | +31-24-679-5100 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2020-08-19) |
* Document for »About Section«: Byondis B.V.. (8/19/20). "Press Release: Byondis Announces Appointment of Chief Financial Officer". Nijmegen. | ||
Record changed: 2024-02-12 |
Advertisement

More documents for Byondis (Group)
- [1] Byondis B.V.. (5/3/22). "Press Release: Byondis and Medac Enter into License and Collaboration and Supply Agreements for Anti-HER2 ADC Trastuzumab Duocarmazine (SYD985)". Nijmegen & Wedel....
- [2] Glycotope GmbH. (7/27/21). "Press Release: Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets". Nijmegen & Berlin....
- [3] Byondis B.V.. (8/19/20). "Press Release: Byondis Announces Appointment of Chief Financial Officer". Nijmegen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top